iShares Biotechnology ETF
IBB
IBB
631 hedge funds and large institutions have $6.3B invested in iShares Biotechnology ETF in 2018 Q3 according to their latest regulatory filings, with 73 funds opening new positions, 195 increasing their positions, 209 reducing their positions, and 46 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
3.29% less ownership
Funds ownership: 67.92% → 64.63% (-3.3%)
4% less funds holding in top 10
Funds holding in top 10: 23 → 22 (-1)
42% less call options, than puts
Call options by funds: $379M | Put options by funds: $654M
Holders
631
Holding in Top 10
22
Calls
$379M
Puts
$654M
Top Buyers
| 1 | +$104M | |
| 2 | +$42.6M | |
| 3 | +$27.5M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$25.3M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$23.9M |
Top Sellers
| 1 | -$225M | |
| 2 | -$181M | |
| 3 | -$105M | |
| 4 |
N
Natixis
Paris,
France
|
-$60.9M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$55.8M |